retatrutide side effects clinical trials 2025 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Retatrutide UK Guide: Key Facts

Note: Intramuscular dosing is typically between 200-600mg per dose and is sometimes used as long term treatment after initial IV therapy

Endocrinology (2011) 152:310312

The commercial features a polar bear discovering his preference for Pepsi Zero Sugar over Coke Zero Sugar in a blind taste test, set to Queens I Want to Break Free. The ad arrives as demand for zero-sugar sodas accelerates among health-conscious consumers, with Pepsi Zero Sugar posting 30.8% growth in 2025, nearly double the zero-sugar cola category

The next few years will determine whether this hope translates into real help for patients and families

Zien wij jouw sollicitatie snel tegemoet

doi: 10.4103/1673-5374.374139 110